New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2014
10:02 EDTAJG, VAR, WDAY, PRGO, YUM, ABV, LULU, BBT, MGM, GLUU, SHW, UNH, STI, BDX, BDN, BRO, COF, CLR, CVD, JNJ, LOGI, PLL, STJ, LMTOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Arthur J. Gallagher (AJG) upgraded to Overweight from Equal Weight at Barclays... Becton Dickinson (BDX) upgraded to Neutral from Underperform at BofA/Merrill... Brandywine Realty (BDN) upgraded to Outperform from Market Perform at Raymond James... Brown & Brown (BRO) upgraded to Overweight from Equal Weight at Barclays... Capital One (COF) upgraded to Conviction Buy from Buy at Goldman... Continental Resources (CLR) upgraded to Buy from Neutral at BofA/Merrill... Covance (CVD) upgraded to Buy from Hold at Jefferies... Johnson & Johnson (JNJ) upgraded to Outperform from Sector Perform at RBC Capital... Logitech (LOGI) upgraded to Equal Weight from Underweight at Barclays... Pall Corp. (PLL) upgraded to Buy from Neutral at BofA/Merrill... St. Jude Medical (STJ) upgraded to Sector Perform from Underperform at RBC Capital... SunTrust (STI) upgraded to Outperform from Market Perform at BMO Capital... UnitedHealth (UNH) upgraded to Buy from Hold at Deutsche Bank... Varian Medical (VAR) upgraded to Neutral from Sell at Citigroup... Workday (WDAY) upgraded to Buy from Neutral at UBS... Yum! Brands (YUM) upgraded to Top Pick from Outperform at RBC Capital... Perrigo (PRGO) upgraded to Buy from Neutral at BofA/Merrill... AmBev (ABV) upgraded to Overweight from Equal Weight at Morgan Stanley... lululemon (LULU) upgraded to Buy from Neutral at DA Davidson... MGM Resorts (MGM) upgraded to Overweight from Equal Weight at Morgan Stanley... Glu Mobile (GLUU) upgraded to Buy from Hold at Craig-Hallum... BB&T (BBT) upgraded to Overweight from Neutral at JPMorgan... Sherwin-Williams (SHW) upgraded to Buy from Hold at KeyBanc... Lockheed Martin (LMT) upgraded to Buy from Neutral at BofA/Merrill.
News For AJG;BDX;BDN;BRO;COF;CLR;CVD;JNJ;LOGI;PLL;STJ;STI;UNH;VAR;WDAY;PRGO;YUM;ABV;LULU;BBT;MGM;GLUU;SHW;LMT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>
October 13, 2014
14:15 EDTJNJEarnings Preview: Johnson & Johnson looks to new drugs to boost Q3 sales
Subscribe for More Information
14:08 EDTJNJJohnson & Johnson technical notes before earnings
Subscribe for More Information
14:02 EDTLULUlululemon's Q3 sales tracking below consensus, says ITG Research
Subscribe for More Information
14:01 EDTAJGArthur J. Gallagher acquires Bennett & Shade
Subscribe for More Information
12:01 EDTYUMOptions with decreasing implied volatility
Options with decreasing implied volatility: EXAS INFY YUM FDO HSY
10:58 EDTLMTLockheed Martin receives $90.6M foreign military sale contract from U.S. Army
Subscribe for More Information
10:08 EDTWDAYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:23 EDTWDAYHP could buy lower valuation company, says Bernstein
Subscribe for More Information
09:03 EDTWDAYWorkday upgraded to Outperform from Market Perform at Northland
Subscribe for More Information
08:40 EDTJNJAlios BioPharma reports positive results for AL-8176 in Phase 2 study
Alios BioPharma presented results from a randomized, double-blind, placebo-controlled Phase 2 challenge study of its oral anti-RSV nucleoside analog AL-8176 this past weekend at the IDWeek 2014 Conference in Philadelphia, PA. The study was conducted in healthy adult volunteers who were infected intranasally with respiratory syncytial virus, or RSV. AL-8176 achieved its primary and secondary endpoints of reduction in viral load and improvement in symptom scores as compared to placebo. AL-8176 was well tolerated with no discontinuations of study drug and no clinically significant laboratory abnormalities. In successfully infected subjects, a rapid and marked reduction in RSV viral load was observed following treatment in all three AL-8176 treated dose groups as compared to placebo. In contrast, successfully infected placebo subjects exhibited a logarithmic increase in RSV RNA with a peak viral load at Day 3.5 following start of dosing with placebo. The mean time to non-detectability of RSV RNA was 1.3-2.3 days for the AL-8176 treatment groups compared to 7.2 days in the placebo group. At discharge, all subjects treated with AL-8176 were RSV RNA undetectable and remained RSV RNA undetectable upon follow-up on Days 16 and 28. The viral load reduction in infected subjects across all AL-8176 dosing regimens was associated with concomitant improvements in RSV symptom scores and reductions in mucus weight. On September 30, Johnson & Johnson announced a definitive agreement to acquire Alios.
08:27 EDTWDAYWorkday upgraded to Outperform from Market Perform at Northland
Subscribe for More Information
08:05 EDTJNJBristol-Myers, Pharmacyclics, Janssen announce clinical collaboration
Bristol-Myers Squibb Company (BMY), Pharmacyclics, Inc. (PCYC), and Janssen Research & Development, LLC (JNJ) announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO in combination with IMBRUVICA, an oral Bruton's tyrosine kinase inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia. Bristol-Myers Squibb has proposed the name OPDIVO, which if approved by health authorities, will serve as the trademark for the investigational drug, nivolumab. OPDIVO is part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system. Each agent has individually shown activity against hematologic malignancies in clinical trials; pre-clinical evidence suggests OPDIVO and IMBRUVICA may have the potential for additive treatment effects in patients with hematologic malignancies. The study will be conducted by Janssen. Additional details of the collaboration were not disclosed.
08:04 EDTBDXBD acquires GenCell Biosystems
Subscribe for More Information
07:25 EDTJNJ, STJEuropean Association of Cardiothoracic Surgery to hold annual meeting
28th EACTS Annual Meeting is being held in Milan, Italy on October 11-15.
07:19 EDTCOFAmEx, Capital One profits seen boosted by credit card 'sweet spot,' WSJ says
Credit card players such as American Express (AXP) and Capital One (COF), as well as banks with significant card units like JPMorgan (JPM), stand to benefit from the U.S. card industry's "sweet spot" of moderate economic growth, low interest rates and consumers who are better managing payments while growing their spending, said The Wall Street Journal, which noted that consulting firm R.K. Hammer estimates U.S. card issuers' revenue will grow 9% this year to $158.6B. Other U.S. banks with credit card units include Bank of America (BAC), Citigroup (C), and Wells Fargo (WFC) and other card companies include Visa (V) and MasterCard (MA). Reference Link
07:15 EDTJNJ, UNHNational Association of Corporate Directors to hold a conference
Subscribe for More Information
07:13 EDTJNJBioFlorida to hold a conference
Subscribe for More Information
06:50 EDTWDAYWorkday upgraded to Outperform from Market Perform at Northland
Subscribe for More Information
06:25 EDTMGMMGM Resorts win in Japan could add $11 per share, says Citigroup
Citigroup estimates shares of MGM Resorts could rally $11 should the company win a gaming license in Osaka, Japan. Citi expects the gaming bill in Japan to be passed in November, and notes MGM is a major candidate in Osaka. The firm says the Macau slowdown has the least impact on MGM. It lowered its price target for shares to $31 from $32 and keeps a Buy rating on the name.
00:04 EDTCOFBanking regulators want more disclosure on auto loans, Reuters says
Banking regulators are requesting that banks provide more details on their auto loan portfolios, says Reuters. Balances remaining on auto loans are rising and about a fifth of the loans are subprime, added Reuters. Publicly traded companies in the space include Bank of America (BAC), Citigroup (C), Capital One (COF), JPMorgan (JPM), U.S. Bancorp (USB) and Wells Fargo (WFC). Reference Link
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use